Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy

In this paper, we extend the model of the dynamics of drug resistance in a solid tumor that was introduced by Lorz et al. (Bull Math Biol 77:1–22, 2015). Similarly to the original, radially symmetric model, the quantities we follow depend on a phenotype variable that corresponds to the level of drug resistance. The original model is modified in three ways: (i) We consider a more general growth term that takes into account the sensitivity of resistance level to high drug dosage. (ii) We add a diffusion term in space for the cancer cells and adjust all diffusion terms (for the nutrients and for the drugs) so that the permeability of the resource and drug is limited by the cell concentration. (iii) We add a mutation term with a mutation kernel that corresponds to mutations that occur regularly or rarely. We study the dynamics of the emerging resistance of the cancer cells under continuous infusion and on–off infusion of cytotoxic and cytostatic drugs. While the original Lorz model has an asymptotic profile in which the cancer cells are either fully resistant or fully sensitive, our model allows the emergence of partial resistance levels. We show that increased drug concentrations are correlated with delayed relapse. However, when the cancer relapses, more resistant traits are selected. We further show that an on–off drug infusion also selects for more resistant traits when compared with a continuous drug infusion of identical total drug concentrations. Under certain conditions, our model predicts the emergence of a heterogeneous tumor in which cancer cells of different resistance levels coexist in different areas in space.

[1]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[2]  J. Goldie,et al.  A model for the resistance of tumor cells to cancer chemotherapeutic agents , 1983 .

[3]  Mikko Niemi,et al.  Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 , 2013, Genome Medicine.

[4]  M. Nowak,et al.  Evolution of resistance to cancer therapy. , 2006, Current pharmaceutical design.

[5]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[6]  Martin A Nowak,et al.  Evolution of Resistance During Clonal Expansion , 2006, Genetics.

[7]  J. Hinchion,et al.  Releasing pressure in tumors: what do we know so far and where do we go from here? A review. , 2014, Cancer research.

[8]  C. Swanton,et al.  Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications , 2013, Genome Medicine.

[9]  Guillaume Lambert,et al.  Cell motility and drug gradients in the emergence of resistance to chemotherapy , 2013, Proceedings of the National Academy of Sciences.

[10]  B. Perthame,et al.  Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[11]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[12]  A. Radunskaya,et al.  Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments , 2013, 1312.3023.

[13]  D. Levy,et al.  An elementary approach to modeling drug resistance in cancer. , 2010, Mathematical biosciences and engineering : MBE.

[14]  Urszula Ledzewicz,et al.  Optimal Control for Mathematical Models of Cancer Therapies: An Application of Geometric Methods , 2015 .

[15]  Doron Levy,et al.  The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  G. Mickisch Multidrug Resistance , 1996, Der Urologe A.

[17]  Michael Travisano,et al.  Adaptive radiation in a heterogeneous environment , 1998, Nature.

[18]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[19]  P. Jabin,et al.  Selection-Mutation dynamics with spatial dependence , 2016, 1601.04553.

[20]  L. Liotta,et al.  Mechanism of Cell Adaptation: When and How Do Cancer Cells Develop Chemoresistance? , 2011, Cancer journal.

[21]  N. Komarova,et al.  Stochastic modeling of drug resistance in cancer. , 2006, Journal of theoretical biology.

[22]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[23]  Leilei Peng,et al.  Holographic optical coherence imaging of rat osteogenic sarcoma tumor spheroids. , 2004, Applied optics.

[24]  S. Bates,et al.  Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. , 2000, Biochimica et biophysica acta.

[25]  Jan Paul Medema,et al.  Cancer stem cells: The challenges ahead , 2013, Nature Cell Biology.

[26]  E. Brodie,et al.  CORRELATIONAL SELECTION FOR COLOR PATTERN AND ANTIPREDATOR BEHAVIOR IN THE GARTER SNAKE THAMNOPHIS ORDINOIDES , 1992, Evolution; international journal of organic evolution.

[27]  S. Jonathan Chapman,et al.  Mathematical Models of Avascular Tumor Growth , 2007, SIAM Rev..

[28]  Alissa M. Weaver,et al.  Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment , 2006, Cell.

[29]  M. Chaplain,et al.  Continuous and Discrete Mathematical Models of Tumor‐Induced Angiogenesis , 1999 .

[30]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[31]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[32]  Shannon M. Mumenthaler,et al.  A high-content image-based method for quantitatively studying context-dependent cell population dynamics , 2016, Scientific Reports.

[33]  B. Perthame,et al.  Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies , 2012, 1207.0923.

[34]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[35]  Sean C. Bendall,et al.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.

[36]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[37]  L. D. Pillis,et al.  A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .

[38]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[39]  J. Panetta,et al.  A mathematical model of drug resistance: heterogeneous tumors. , 1998, Mathematical biosciences.

[40]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[41]  M. Gottesman,et al.  The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .

[42]  B. Perthame,et al.  Asymptotic analysis of a selection model with space , 2014, 1407.5870.

[43]  S Gallivan,et al.  A mathematical model of the development of drug resistance to cancer chemotherapy. , 1987, European journal of cancer & clinical oncology.

[44]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[45]  O. Jensen,et al.  On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space–time” dimension of MDR , 2009, European Biophysics Journal.

[46]  A. Grothey Defining the role of panitumumab in colorectal cancer , 2006 .

[47]  R. Arceci Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[48]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.

[49]  William Pao,et al.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.

[50]  M. Gottesman,et al.  The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[51]  Beverly A. Teicher,et al.  Cancer Drug Resistance , 2006 .

[52]  A. Świerniak,et al.  Mathematical modeling as a tool for planning anticancer therapy. , 2009, European journal of pharmacology.

[53]  Doron Levy,et al.  Simplifying the complexity of resistance heterogeneity in metastasis. , 2014, Trends in molecular medicine.